Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-08, Stock:ABBV, The news for the past five days is as follows:
2018-11-01: NEWS1: AbbVie&apos;s Leukemia Treatment Gets EU Regulatory Nod; Shares Rise 3%.NEWS2: Bottom fishers, these stocks are within 5% of their 52-week lows.NEWS3: Pre-Market Earnings Report for November 2, 2018 :  XOM, CVX, BABA, ABBV, DUK, ENB, IMO, WLTW, FTS, CBOE, VST, STX.NEWS4: Pre-Market Earnings Report for November 2, 2018 :  XOM, CVX, BABA, ABBV, DUK, ENB, IMO, WLTW, FTS, CBOE, VST, STX.NEWS5: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, PVG, COCP, ABBV and ADNT.NEWS6: Interesting ABBV Put And Call Options For December 14th.NEWS7: Interesting ABBV Put And Call Options For December 14th.NEWS8: Today’s Research Reports on Stocks to Watch: Aeterna Zentaris and AbbVie.NEWS9: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal.NEWS10: AbbVie, Roche combo treatment meets main goal of leukemia trial.NEWS11: AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy.NEWS12: AbbVie: VENCLYXTO Plus Rituximab Gets Europe Approval To Treat CLL Patients.NEWS13: AbbVie: VENCLYXTO Plus Rituximab Gets Europe Approval To Treat CLL Patients.
2018-11-02: NEWS1: 5 Income Stocks for Massive Payouts and Steady Growth.NEWS2: 5 Income Stocks for Massive Payouts and Steady Growth.NEWS3: AbbVie Stock Jumps Higher on Q3 Earnings Beat.NEWS4: AbbVie Stock Jumps Higher on Q3 Earnings Beat.NEWS5: AbbVie Inc (ABBV) Q3 2018 Earnings Conference Call Transcript.NEWS6: AbbVie Inc (ABBV) Q3 2018 Earnings Conference Call Transcript.NEWS7: AbbVie's Q3 Update: 3 Things You Need to Know.NEWS8: AbbVie's Q3 Update: 3 Things You Need to Know.NEWS9: 5 Income Stocks for Massive Payouts and Steady Growth.NEWS10: SHAREHOLDER ALERT: OPK PM QRTEA TRCO PVG COCP ABBV ALNY MGTI CHGG CWH DY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS11: AbbVie&apos;s Q3 Update: 3 Things You Need to Know.NEWS12: AbbVie Inc (ABBV) Q3 2018 Earnings Conference Call Transcript.NEWS13: AbbVie sees hit to Humira sales from European competition.NEWS14: AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up.NEWS15: AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up.NEWS16: AbbVie sees hit to Humira sales from European competition.NEWS17: ABBV LOSSES ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against AbbVie Inc.; Important Deadline – ABBV.NEWS18: AbbVie Best-Seller Humira Shows Its Mortality.NEWS19: AbbVie&apos;s (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up.NEWS20: AbbVie Stock Jumps Higher on Q3 Earnings Beat.NEWS21: CLASS ACTION UPDATE for ABBV, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS22: 3 Stocks That Got Dividend Hikes This Week.NEWS23: What to watch in the markets: Nov. 2.NEWS24: AbbVie Earnings, Revenue beat in Q3.NEWS25: MARKETS: Today's job numbers might have been too good and could spook stocks.NEWS26: Humira biosimilars available at up to 80 percent discount in Europe: AbbVie.NEWS27: AbbVie (ABBV) Tops Q3 Earnings Estimates.NEWS28: AbbVie (ABBV) Tops Q3 Earnings Estimates.NEWS29: AbbVie expects double-digit earnings growth in 2019.NEWS30: AbbVie (ABBV) Tops Q3 Earnings Estimates.NEWS31: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS32: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS33: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS34: AbbVie: 3Q Earnings Snapshot.NEWS35: AbbVie shares jump 3% premarket after earnings beat and higher guidance.NEWS36: AbbVie Reports Third-Quarter 2018 Financial Results.NEWS37: Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.0% Sensitive.NEWS38: Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.0% Sensitive.NEWS39: Dow jumps 150 points after strong jobs report, but Apple's loss drags down the Nasdaq.NEWS40: US stock futures rise after better-than-expected jobs report and trade optimism.NEWS41: Dow set for 300-point jump after Trump reportedly asks for draft on US-China trade deal.NEWS42: Dow set for triple-digit gains at the open as investors focus on nonfarm payrolls.NEWS43: [$$] AbbVie/arthritis drugs: copycat flap.NEWS44: A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18).
2018-11-05: NEWS1: CLASS ACTION UPDATE for OPK, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS2: INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS3: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, MCHP, ABBV, ALNY and CHGG.NEWS4: AbbVie Rises 3%.NEWS5: What's Ahead for AbbVie After Earnings and Revenue Beat?.NEWS6: November 20th AbbVie Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV.
2018-11-06: NEWS1: ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm.NEWS2: AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta.NEWS3: NOVEMBER 20 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS4: Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA.NEWS5: Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA.NEWS6: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS7: Today's Research Reports on Trending Tickers: AbbVie and AstraZeneca.
2018-11-07: NEWS1: Better Buy: Eli Lilly and Company vs. AbbVie Inc..NEWS2: Better Buy: Eli Lilly and Company vs. AbbVie Inc..NEWS3: DEADLINE ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS4: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV.NEWS5: Better Buy: Eli Lilly and Company vs. AbbVie Inc..NEWS6: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, ABBV, MGTI and JT.NEWS7: All this 500,000-square-foot Berkeley biotech project needs is a developer.NEWS8: 7 Healthcare Stocks Soaring on Election Results.NEWS9: What AbbVie’s Bottom Line Trend Indicates.NEWS10: A Look at AbbVie’s Operational Performance.NEWS11: How AbbVie Is Positioned in November.NEWS12: AbbVie Rises 3%.NEWS13: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018.NEWS14: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie.

Answer: Rise